HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s stock price traded up 6.9% during mid-day trading on Monday . The company traded as high as $14.75 and last traded at $14.67. 41,471 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 107,935 shares. The stock had previously closed at $13.72.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded shares of HUTCHMED from a "hold" rating to a "buy" rating in a report on Friday, March 21st.
View Our Latest Stock Analysis on HUTCHMED
HUTCHMED Price Performance
The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68. The stock's 50-day moving average is $14.81 and its 200 day moving average is $16.00.
Institutional Investors Weigh In On HUTCHMED
A number of hedge funds and other institutional investors have recently bought and sold shares of HCM. Jane Street Group LLC lifted its stake in shares of HUTCHMED by 362.2% in the third quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock valued at $1,305,000 after purchasing an additional 49,366 shares during the period. XY Capital Ltd acquired a new stake in shares of HUTCHMED in the 4th quarter worth approximately $673,000. ABC Arbitrage SA purchased a new position in HUTCHMED in the 4th quarter valued at approximately $500,000. Renaissance Technologies LLC boosted its position in HUTCHMED by 18.4% during the fourth quarter. Renaissance Technologies LLC now owns 188,539 shares of the company's stock worth $2,717,000 after purchasing an additional 29,239 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in HUTCHMED in the fourth quarter valued at $261,000. Institutional investors and hedge funds own 8.82% of the company's stock.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
